INNOVIVA, INC. Selling, General and Administrative Expense
INNOVIVA, INC. (INVA) reported Selling, General and Administrative Expense of $34.57 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-05
- INNOVIVA, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $34.57M, a 30.89% increase year-over-year.
- INNOVIVA, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $32.44M, a 17.99% increase year-over-year.
- INNOVIVA, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $32.12M, a 2.55% increase year-over-year.
- INNOVIVA, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $27.29M, a 4.09% increase year-over-year.
- INNOVIVA, INC. selling, general and administrative expense for fiscal 2025 was $113.32M, a 2.05% decline from fiscal 2024.
- INNOVIVA, INC. selling, general and administrative expense for fiscal 2024 was $115.69M, a 17.77% increase from fiscal 2023.
- INNOVIVA, INC. selling, general and administrative expense for fiscal 2023 was $98.23M, a 54.60% increase from fiscal 2022.
- INNOVIVA, INC. selling, general and administrative expense for fiscal 2022 was $63.54M, a 292.52% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $34.57M 10-Q · filed 2026-08-05 | $67.01M 10-Q · filed 2026-08-05 | $99.13M derived: sum of 3 quarters · filed 2026-08-05 | $126.42M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $32.44M 10-Q · filed 2026-05-06 | $64.56M derived: sum of 2 quarters · filed 2026-05-06 | $91.85M derived: sum of 3 quarters · filed 2026-05-06 | $118.27M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $32.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $59.41M derived: sum of 2 quarters · filed 2026-02-25 | $85.83M derived: sum of 3 quarters · filed 2026-08-05 | $113.32M 10-K · filed 2026-02-25 |
| 2025-09-30 | $27.29M 10-Q · filed 2025-11-05 | $53.70M derived: sum of 2 quarters · filed 2026-08-05 | $81.19M 10-Q · filed 2025-11-05 | $112.52M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $26.41M 10-Q · filed 2026-08-05 | $53.90M 10-Q · filed 2026-08-05 | $85.23M derived: sum of 3 quarters · filed 2026-08-05 | $111.45M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $27.49M 10-Q · filed 2026-05-06 | $58.82M derived: sum of 2 quarters · filed 2026-05-06 | $85.04M derived: sum of 3 quarters · filed 2026-05-06 | $112.78M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $31.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $57.55M derived: sum of 2 quarters · filed 2026-02-25 | $85.28M derived: sum of 3 quarters · filed 2026-02-25 | $115.69M 10-K · filed 2026-02-25 |
| 2024-09-30 | $26.22M 10-Q · filed 2025-11-05 | $53.96M derived: sum of 2 quarters · filed 2025-11-05 | $84.36M 10-Q · filed 2025-11-05 | $110.68M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $27.74M 10-Q · filed 2025-08-06 | $58.15M 10-Q · filed 2025-08-06 | $84.46M derived: sum of 3 quarters · filed 2026-02-25 | $113.10M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $30.41M 10-Q · filed 2025-05-07 | $56.72M derived: sum of 2 quarters · filed 2026-02-25 | $85.36M derived: sum of 3 quarters · filed 2026-02-25 | $108.90M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $26.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $54.95M derived: sum of 2 quarters · filed 2026-02-25 | $78.50M derived: sum of 3 quarters · filed 2026-02-25 | $98.23M 10-K · filed 2026-02-25 |
| 2023-09-30 | $28.64M 10-Q · filed 2024-11-06 | $52.18M derived: sum of 2 quarters · filed 2024-11-06 | $71.91M 10-Q · filed 2024-11-06 | $89.37M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $23.54M 10-Q · filed 2024-07-31 | $43.28M 10-Q · filed 2024-07-31 | $60.73M derived: sum of 3 quarters · filed 2025-02-26 | $88.54M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $19.73M 10-Q · filed 2024-05-08 | $37.19M derived: sum of 2 quarters · filed 2025-02-26 | $65.00M derived: sum of 3 quarters · filed 2025-02-26 | $76.78M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $17.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $45.26M derived: sum of 2 quarters · filed 2025-02-26 | $57.05M derived: sum of 3 quarters · filed 2025-02-26 | $63.54M 10-K · filed 2025-02-26 |
| 2022-09-30 | $27.81M 10-Q · filed 2023-11-01 | $39.59M derived: sum of 2 quarters · filed 2023-11-01 | $46.08M 10-Q · filed 2023-11-01 | $49.20M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | $11.78M 10-Q · filed 2023-08-02 | $18.27M 10-Q · filed 2023-08-02 | $21.39M derived: sum of 3 quarters · filed 2024-03-05 | $24.25M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | $6.49M 10-Q · filed 2023-05-09 | $9.61M derived: sum of 2 quarters · filed 2024-03-05 | $12.46M derived: sum of 3 quarters · filed 2024-03-05 | |
| 2021-12-31 | $3.11M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-05 | $5.97M derived: sum of 2 quarters · filed 2024-03-05 | $16.19M 10-K/A · filed 2024-03-05 | |
| 2021-09-30 | $2.86M 10-Q · filed 2022-11-09 | $13.07M 10-Q · filed 2022-11-09 | ||
| 2020-12-31 | $13.88M 10-K · filed 2023-02-28 | |||
| 2014-03-31 | $22.83M 10-Q · filed 2014-05-07 | $39.30M derived: sum of 2 quarters · filed 2014-05-07 | $51.59M derived: sum of 3 quarters · filed 2014-05-07 | |
| 2013-12-31 | $16.47M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $28.75M derived: sum of 2 quarters · filed 2014-03-03 | $48.44M 10-K · filed 2014-03-03 | |
| 2013-09-30 | $12.28M 10-Q · filed 2013-11-01 | $31.97M 10-Q · filed 2013-11-01 | ||
| 2013-03-31 | $8.31M 10-Q · filed 2014-05-07 | $15.97M derived: sum of 2 quarters · filed 2014-05-07 | $23.73M derived: sum of 3 quarters · filed 2014-05-07 | |
| 2012-12-31 | $7.66M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $15.41M derived: sum of 2 quarters · filed 2014-03-03 | $30.86M 10-K · filed 2014-03-03 | |
| 2012-09-30 | $7.75M 10-Q · filed 2013-11-01 | $23.20M 10-Q · filed 2013-11-01 | ||
| 2011-12-31 | $30.68M 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |